(Press-News.org) The cancer drug bevacizumab (Avastin®) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.
Breast cancer is the most common cause of cancer death among women. If it spreads to other parts of the body it is referred to as "metastatic" and the cancer becomes much more difficult to treat. One promising approach is drugs that target vascular endothelial growth factor (VEGF), a key molecule mediating growth of blood vessels in tumours. At present, trials of drugs that target VEGF are limited to bevacizumab, which is the first drug of this type to be approved for metastatic breast cancer.
To assess the clinical value of bevacizumab in combination with other established chemotherapy drugs, the researchers gathered evidence from seven trials involving a total of 4,032 patients, most of whom had metastatic breast cancer. They found that adding bevacizumab to established drug regimens increased the time to tumour progression or death by between one and six months, depending on the chemotherapy drugs prescribed. However, the researchers found that adding bevacizumab to first- or second-line treatments did not increase overall survival or quality of life.
"At best, adding bevacizumab to standard chemotherapy appears to offer a modest benefit for those with metastatic breast cancer," said lead researcher, Anna Dorothea Wagner, of the Fondation du Centre Pluridisciplinaire d'Oncologie, University Hospital Lausanne, Switzerland. "Whether it can truly be of benefit to the patient is debatable, because it only briefly prolongs progression of the disease. No impact on the patient's overall survival or quality of life has been demonstrated."
According to the researchers, clinical trials testing new drugs for advanced stage breast cancer should follow patients until death in order to understand the impact of new treatments on survival. "The fact that an increase in progression-free survival does not lead to an increase in overall survival suggests that progression-free survival may not be a reliable surrogate for clinical trials in metastatic cancer," said Wagner.
In 2011, the US Food and Drug Administration (FDA) removed breast cancer from indications on the label of bevacizumab, due to concerns about serious side effects and doubts about its benefit in terms of overall survival. By contrast, it is approved for first-line treatment of metastatic breast cancer in Europe, in combination with the cancer drug paclitaxel, as well as in combination with capecitabine for patients with metastatic cancer who are not eligible for treatment with taxanes or anthracyclines.
### END
Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival
2012-07-11
ELSE PRESS RELEASES FROM THIS DATE:
Fewer iron supplements during pregnancy work just as well for preventing anemia
2012-07-11
Taking iron supplements one to three times a week instead of every day is just as effective at preventing anaemia in pregnant women, according to the findings of a new Cochrane systematic review. The authors of the review also showed that women experienced fewer side effects when taking iron supplements intermittently rather than daily.
Lack of iron can cause anaemia in pregnant women, potentially increasing the risk of complications at delivery. It may also be harmful to their babies, through increased risk of low birth weight and even delayed growth and development ...
Drugs used to treat HIV also reduce risk of HIV infection
2012-07-11
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Antiretroviral therapy (ART) is the standard drug treatment for HIV in ...
Cyberwarfare, conservation and disease prevention could benefit from MU researcher's network model
2012-07-11
COLUMBIA, Mo. -- Computer networks are the battlefields in cyberwarfare, as exemplified by the United States' recent use of computer viruses to attack Iran's nuclear program. A computer model developed at the University of Missouri could help military strategists devise the most damaging cyber attacks as well as guard America's critical infrastructure. The model also could benefit other projects involving interconnected groups, such as restoring ecosystems, halting disease epidemics and stopping smugglers.
"Our model allows users to identify the best or worst possible ...
Potential cause of HIV-associated dementia revealed
2012-07-11
WASHINGTON — Researchers at Georgetown University Medical Center appear to have solved the mystery of why some patients infected with HIV, who are using antiretroviral therapy and show no signs of AIDS, develop serious depression as well as profound problems with memory, learning, and motor function. The finding might also provide a way to test people with HIV to determine their risk for developing dementia.
They say the answer, published in the July 11 issue of the Journal of Neuroscience, may ultimately lead to a therapeutic solution that helps these patients as well ...
Metamolecules that switch handedness at light-speed
2012-07-11
A multi-institutional team of researchers that included scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) has created the first artificial molecules whose chirality can be rapidly switched from a right-handed to a left-handed orientation with a beam of light. This holds potentially huge possibilities for the application of terahertz technologies across a wide range of fields, including biomedical research, homeland security and ultrahigh-speed communications.
Chirality is the distinct left/right orientation or "handedness" ...
Not so happy: King penguins stressed by human presence
2012-07-11
King penguins tolerate some, but not all, human interference. Research published in BioMed Central's open access journal, BMC Ecology, investigates the adjustment of a king penguin colony on the protected Possession island in the subantarctic Crozet Archipelago to over 50 years of constant human disturbance.
A team of researchers from the University of Strasbourg, the Centre National de la Recherche Scientifique (CNRS) and the University of Lausanne, compared 15 king penguins (Aptenodytes patagonicus) breeding in areas disturbed daily by humans and 18 penguins breeding ...
Blood-brain barrier less permeable in newborns than adults after acute stroke
2012-07-11
The ability for substances to pass through the blood-brain barrier is increased after adult stroke, but not after neonatal stroke, according to a new study the UCSF that will be published July 11 in the Journal of Neuroscience.
The novel findings may have major implications for drug development and the treatment of neonatal stroke, the researchers said.
The blood-brain barrier is selectively permeable and blocks unwanted molecules from entering into the brain. The selectivity is achieved through fine coordination in function of many transporting systems in endothelial ...
Moderate drinking may reduce risk of rheumatoid arthritis
2012-07-11
Research: Long term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study
Moderate consumption of alcohol is associated with a reduced risk of developing rheumatoid arthritis, suggests a study published on bmj.com today.
The results show that women who regularly consume more than three alcoholic drinks a week for at least 10 years have about half the risk of developing rheumatoid arthritis compared with non-drinkers.
After adjusting for factors such as age, smoking and dietary habits, women who reported drinking more than three ...
Weight gain after quitting smoking higher than previously thought
2012-07-11
Research: Weight gain in smokers after quitting cigarettes: meta-analysis
Editorial: Quitting smoking and gaining weight: the odd couple
Giving up smoking is associated with an average weight gain of 4-5 kg after 12 months, most of which occurs within the first three months of quitting, finds a study published on bmj.com today.
Although this figure is higher than previously thought, an accompanying editorial argues that the health benefits of quitting far outweigh this modest gain in body weight and should not deter people from quitting.
It is well known that ...
Not all brand-consumer relationships are created equal, says University of Toronto study
2012-07-11
Toronto – Not all brand–consumer relationships are created equal.
Marketers who realize this will be in a better position to retain customers and improve the perceptions of consumers who are unhappy with a brand's service or product, says a new paper from the University of Toronto.
Consumers form connections with brands in ways that mirror social relationships.
How consumers evaluate a brand depends heavily on whether the brand adheres to—or violates—the implicit relationship agreement.
Pankaj Aggarwal, a marketing professor at the Rotman School of Management and ...